GRAY Stock Price, News & Analysis

Graybug Vision, Inc. (Nasdaq: GRAY) announced the appointment of Bettina Maunz as Chief People Officer, effective immediately. Maunz, who has been a consultant since August 2019, will also lead communications and contribute to the executive team. CEO Frederic Guerard emphasized her leadership experience will enhance employee engagement and team performance. Maunz's previous roles include senior positions in communications at Novartis and Alcon, where she significantly impacted organizational culture and corporate responsibility. Graybug is focused on innovative treatments for retinal and optic nerve diseases.

Graybug Vision (Nasdaq: GRAY) announced the completion of patient treatment in its Phase 2b ALTISSIMO trial for GB-102, aimed at addressing wet age-related macular degeneration (AMD). Of the 56 enrolled patients, 50 completed the 12-month treatment phase, with 58% opting for a six-month extension. Topline data is expected in Q2 2021, which will assess the drug's durability and safety compared to traditional treatments requiring up to 12 injections yearly. GB-102 is designed for biannual administration, potentially easing treatment burdens for AMD patients.

Graybug Vision, a clinical-stage biopharmaceutical company, announced CEO Fred Guerard will participate in a fireside chat ahead of the virtual Piper Sandler Healthcare Conference on December 1-3, 2020. The recorded chat will be accessible starting November 23, 2020, via the company's website and will remain available for 14 days post-conference. Graybug focuses on developing innovative treatments for retinal diseases, utilizing proprietary ocular delivery technologies for extended drug release, including lead candidate GB-102 for age-related macular degeneration.

Graybug Vision, Inc. (Nasdaq: GRAY) reported a net loss of $4.7 million for Q3 2020, improving from $10.2 million in Q3 2019. The company's net loss for the nine months ended September 30, 2020, was $18.4 million, down from $26.8 million a year prior. Graybug raised over $92 million from its IPO, enhancing its cash reserves to $95 million. The lead product candidate, GB-102, is in Phase 2b development and aims to reduce treatment frequency for retinal diseases. Major milestones are anticipated in 2021, including the initiation of Phase 3 trials.

Graybug Vision (Nasdaq: GRAY) announced the appointment of three new Board members: Christina Ackermann, Eric Bjerkholt, and Julie Eastland. They replace former members Emmett Cunningham, Chau Khuong, and Cameron Wheeler, enhancing the board's expertise in healthcare and biotechnology. Graybug is entering a pivotal phase following its initial public offering, aiming to advance its pipeline of ophthalmic drugs. Key products include GB-102, targeting retinal diseases with a six-month dosing regimen, and GB-401 for glaucoma with a similar dosing schedule.

Graybug Vision announced the pricing of its upsized initial public offering (IPO) of 5,625,000 shares at $16.00 per share, aiming for gross proceeds of $90 million. The shares will trade on Nasdaq under the symbol GRAY starting September 25, 2020. The offering includes a 30-day option for underwriters to purchase an additional 843,750 shares. Graybug, focused on innovative treatments for retinal diseases, plans to utilize the funds to further develop its drug candidates, enhancing treatment regimens for chronic vision-threatening conditions.